Real-time funding, M&A, exec moves & hiring — the signals that move deals
More real-time opportunities that match your ICP — every funding, M&A, and exec move the moment it breaks, with the verified contacts to reach out first.
Funding, M&A, exec moves & hiring — every signal Fundz sees, the moment it happens. See who’s in your market, who to reach, and why now.
UCB to acquire Neurona Therapeutics for epilepsy focus
PRIVATEApr 17, 2026•3 months ago
Acquiring Company
UCB
Acquired Company
Neurona Therapeutics
South San FranciscoSoftwareData And AnalyticsBiotechnology
Description
UCB has announced a definitive agreement to acquire Neurona Therapeutics, enhancing its epilepsy portfolio with the addition of NRTX-1001. The acquisition will advance UCB's regenerative medicine strategy and aims to provide innovative solutions for patients with high unmet needs. UCB will pay $650 million upfront, with potential future payments totaling $500 million. The transaction is expected to close by the end of Q2 2026, pending regulatory approvals.
Company Information
Company
UCB
About
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 8,000 people in approximately 40 countries, the company generated revenue of €5.3 billion in 2020. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news.
South San FranciscoSoftwareData And AnalyticsBiotechnology